Scalper1 News
Specialty drugmaker and IBD 50 stock Shire (SHPG) has rejected three takeover offers from U.S. big pharma AbbVie (ABBV), with the most recent valued at $46.5 billion, the companies announced Friday. Shire’s stock vaulted nearly 18% in early trading on the stock market today, to an all-time high near 225.50, while AbbVie stock was up a fraction. The two companies have been talking since early May, when AbbVie offered 39.50 British pounds per Shire Scalper1 News
Scalper1 News